Trial Profile

A clinical study of PD-1 antibody SHR-1210 combined with apatinib in first-line treatment of advanced lung squamous carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
Indications Carcinoma; Lung cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

13 Jul 2020 Status changed from recruiting to completed.
31 May 2020 Interim Results (data cutoff Feb 10, 2020; n=26), evaluating the efficacy and safety of SHR-1210 in combination with apatinib, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
27 Jun 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com